Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	25905
Country	Japan

Received	2016-03-26 16:42
Peer-Review Started	2016-03-26 18:14
To Make the First Decision	2016-06-06 17:24
Return for Revision	2016-06-07 17:12
Revised	2016-06-21 05:14
Second Decision	2016-07-11 11:59
Accepted by Journal Editor-in-Chief	2016-07-11 12:07
Accepted by Executive Editor-in-Chief	2016-07-22 11:11
Articles in Press	2016-07-22 11:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-08-28 09:29
Publish the Manuscript Online	2016-09-12 10:43

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Role of targeted therapy in metastatic colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Yoshihito Ohhara, Naoki Fukuda, Satoshi Takeuchi, Rio Honma, Yasushi Shimizu, Ichiro Kinoshita and Hirotoshi Dosaka-Akita
Funding Agency and Grant Number
Corresponding Author	Yoshihito Ohhara, MD, Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. yoshihito-ohhara@kkr-smc.com
Key Words	Metastatic colorectal cancer; Aflibercept; Ramucirumab; Regorafenib; Cetuximab; Panitumumab; Targeted therapy; Bevacizumab
Core Tip	The development of molecular targeted agents contributes to prolonging survival of patients with metastatic colorectal cancer (mCRC). One anti-vascular endothelial growth factor agent, bevacizumab, and two anti-epidermal growth factor receptor (EGFR) agents, cetuximab and panitumumab, have demonstrated clinical benefits in first-line, second-line, or salvage therapy in combination with cytotoxic chemotherapy. Moreover, RAS mutation has been proven to be a negative biomarker for anti-EGFR therapy in recent retrospective analyses. This article summarizes the evidence from large clinical trials and highlights the benefit of the molecular targeted agents in patients with mCRC.
Publish Date	2016-09-12 10:43
Citation	Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655
URL	http://www.wjgnet.com/1948-5204/full/v8/i9/642.htm
DOI	http://dx.doi.org/10.4251/wjgo.v8.i9.642

Full Article (PDF)	WJGO-8-642.pdf
Full Article (Word)	WJGO-8-642.doc
Manuscript File	25905-Review.docx
Answering Reviewers	25905-Answering reviewers.pdf
Audio Core Tip	25905-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25905-Conflict-of-interest statement.pdf
Copyright License Agreement	25905-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25905-Language certificate.pdf
Peer-review Report	25905-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	25905-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	25905-Scientific misconduct check.pdf
Scientific Editor Work List	25905-Scientific editor work list.pdf